Substance use has turned out to be one of the growing social problems of the present society cutting across all sorts of boundaries of the world. Like in other parts of the globe, substance use is highly prevalent in India with the society of the Kashmir Valley being no exception to this growing pathological phenomenon. It has been observed that there has been a surge in substance use in our society, especially the youth over the past few years.
From a dermatological point of view, skin eruptions induced by illicit drugs can be encountered in a variety of clinical settings. Dermatoses in this group of patients may range from pharmacological side effects of the drug to cutaneous complications of drug administration, or the lesions can be due to adulterants or infectious agents mixed with the drug. Owing to the paucity of literature regarding the prevalence and pattern of dermatological manifestations among substance users, the present study was designed and is the first of its kind in Kashmir Valley, with an aim to offer a novel look into the trends in the pattern of dermatoses among substance users. All the studies that we came across, during an extensive review of literature, have focused on a single disorder and never on an entire group of disorders. In this one-of-a-kind study, we focused on dermatological manifestations among substance users as a comprehensive cluster and attempted to study these disorders as a group.
Aims and Objectives
To determine the prevalence and pattern of dermatological manifestations among substance users across Kashmir Valley.
Materials and Methods
It was a cross sectional study for a period of 18 months (November 2018 to April 2020). Native Kashmiri population was recruited and samples were taken from patients of all age groups and gender, admitted at various drug de addiction centres (DDC) from multiple districts within Kashmir valley, after obtaining Institutional ethical clearance. Stratification of Kashmir Valley into three zones and distribution of drug de addiction facilities were done for convenience sampling [Figure A].
The frequency of visits to various drug de-addiction facilities across Kashmir Valley was determined by the inflow of patients at these centers on the basis of data given by the Department of Psychiatry, Government medical college (GMC), Srinagar, and various other drug de-addiction centers across the valley. Based on the past and present IPD and OPD records, the highest number of admissions was seen at drug de-addiction center, Institute of Mental Health and Neuroscience (IMHANS), Government Medical College, Srinagar, during the study period as this treatment facility catered to most of the population undergoing treatment for substance use and was also the referral center for the whole valley. Weekly visits were made over a span of 18 months at DDC IMHANS, GMC, Srinagar. Monthly visits were made to the drug de-addiction facilities under Jammu and Kashmir Police available at Police Control Room (PCR), Batamaloo, Srinagar, and Youth Development and Rehabilitation Centre, Eidgah, Srinagar, which had the second highest number of admissions in the valley during the period of this study. Three monthly visits were made to the rest of the drug de-addiction centers, i.e., GMC Anantnag and GMC Baramulla as well as drug de-addiction centers which were under Jammu and Kashmir police at district police lines Anantnag, and old hospital Baramulla.
A detailed history was elicited in each case regarding age, sex, occupation, and socioeconomic status with a particular reference to cutaneous complaints including lesion type, onset, duration, evolution, and progression. Past history and associated comorbidities were also recorded on a predesigned pro forma. General physical examination, systemic examination, and a detailed mucocutaneous examination of all patients was carried out after taking consent. Routine laboratory investigations including serology for hepatitis B, hepatitis C, and HIV were also conducted. Diascopy and dermatoscopy wherever needed were used as a means of examination. Skin biopsy was performed in cases of a diagnostic dilemma.
The recorded data was compiled and entered in a spreadsheet (Microsoft Excel) and then exported to the data editor of SPSS Version 20.0 (SPSS Inc., Chicago, Illinois, USA). Continuous variables were expressed as mean ± SD, and categorical variables were summarized as frequencies and percentages. Graphically, the data was presented by bar and pie diagrams. Chi-square test was employed for comparing the prevalence of various parameters. A P value of less than 0.05 was considered statistically significant. All P values were two-tailed.
The study included a total of 710 cases with 657 males (92.5%) and 53 females (7.5%). The male/female ratio was 12.4:1. The mean age of patients was 25.2 ± 7.05 years.
Socio-demographic characteristics of study patients are given in Table 1.
Comorbidities and serology of study patients are given in Table 2.
49.4% patients were polysubstance users, while 50.6% patients used a single substance only. Opioids were the most common substance used among which heroin had the highest number of cases, while cannabis was found to be the second most common substance (47%). Tramadol (18.9%), codeine (3.7%), and tapentadol (1.8%) were the other opioids used [Table 3]. Among heroin users, 42.3% were injectable drug users (IDUs), while in the rest of the cases heroin was perpetuated via smoking (57.7%). Smoking was also the mode of substance abuse among all patients of cannabis use in this study (100%). Other substances abused in this study were taken orally except cocaine where snorting was carried out. The duration of substance use ranged between 1 month and 16 years with the mean duration being 2.8 ± 2.56 years [Figure 1].
The prevalence and pattern of dermatological manifestations among study patients are given in Table 4. Heroin was the most common substance used by cases in this study. Specific dermatological manifestations and their prevalence among heroin users are shown in [Figure 2].
Cannabis was found to be the second most common substance used by the cases in the current study (47%). Specific dermatological manifestations and their prevalence in this group are shown in [Figure 3].
Pruritus was found to be the most common dermatological manifestation overall and was statistically significant (P < 0.001) among heroin users. The presence of pruritus had a temporal relation with substance use and was seen most commonly during the first few months of heroin use with 53% having pruritus in the first 3 months of heroin use. There was a predilection for pruritus toward the nasal and facial area followed by genitals. This in turn led to the presence of prurigo [41 (8.5%)] in some of these cases where 26 such cases were biopsy-documented [Figure 4]. The mean age of patients presenting with pruritus was 24.1 ± 5.27 years, and the majority of patients were in the age-group of 21–30 years (64%) [Figure 5]. Among cases of pruritus, 36% had mild, 47% had moderate, while 17% had severe pruritus on the basis of 12-point pruritus severity scale (12 PSS).
Some lesions were specifically seen among injectable drug users (IDUs) [Figure 6]. Stigmata of injection drug use (IDU) with the presence of track marks and sooting tattoos were observed in 93.1% of injectable heroin users [Figure 7].
Deep circular punched-out looking atrophic scars secondary to skin popping were seen exclusively in injectable heroin users (30.7%) [Figure 8].
Active skin ulcers and skin and soft tissue infections (SSTI) at the injection site were present in injectable heroin users (18.8%) [Figure 9]. Such lesions had a predilection toward forearms and arms followed by legs. Most of the lesions were infective with staphylococcus aureus and anaerobes as the most common agents isolated on cultures.
Similarly, puffy hand syndrome developing post-chronic intravenous heroin use was exclusively seen (8.7%).
Hyperhidrosis localized to palms followed by generalized hyperhidrosis was seen in a few cases in the present study specifically in opioid users, where it was seen in 39.6% of heroin users.
Oral involvement was fairly common in heroin users where the mode of administration was smoking. Tooth decay and periodontal disease could be seen in many of these heroin users (19%). Some of the heroin users presented with soft creamy patches or pseudo-membranes in the oral mucosa consistent with the clinical picture of oral thrush. Culture on Sabouraud dextrose agar (SDA) medium revealed both Candida albicans and non-albicans species (6.2%), out of which 1.1% patients were positive for HIV serology. Stomatitis nicotinica, characterized by palatal erythema with papules secondary to heroin and cannabis smoking, was also present in 13.6% and 13.8%, respectively (P = 0.941). Similarly, black hairy tongue secondary to heavy heroin and cannabis smoking was observed in 4.8% heroin users and 3.2% cannabis users [Figure 10].
Staining over the fingers and nails present with hyperpigmentation due to smoking could be seen in both cannabis (64.4%) and heroin users (57.1%), however, statistically significant among cannabis users (P < 0.002) compared to heroin users [Figure 11].
Periorbital hypermelanosis was seen in many of the cases of cannabis use in this study (13.7%). Frictional callosities of the hands, especially thumb (12.2%), developed secondary to hand rubbing of cannabis, and excessive lighter use was also seen in cannabis smokers. Acne vulgaris in cannabis users was less (9.2%) compared to total users and statistically significant (P < 0.001). Hesitation cuts were seen in 16.3% of substance users, among which 36% of the patients had associated psychological comorbidities, predominantly bipolar-associated disorder diagnosed, while dermatitis artefacta could be seen in 2.1% cases with 53% having associated psychological comorbidities, predominantly depression diagnosed by a psychiatrist in both groups of patients.
Dermatological disorders like pityriasis capitis (3.7%), dermatophytosis (2.1%), hand eczema (3.3%) and other disorders (psoriasis, vitiligo, and eczema) (2%) were also seen in the study.
The pattern of substance use has seen a shift toward opioid use being highly prevalent in Kashmir Valley with heroin being most commonly abused among them compared to cannabis, being the most common substance used in the past. Similarly, in our study the most common substance used by study cases was heroin (n = 515) followed by cannabis (n = 334). In current times, clinicians often find it difficult to detect these dangerous practices of substance use among patients, thus making it important to recognize dermatological manifestations of substance use for more effective diagnosis and practices. All the studies that we came across, during an extensive review of literature, have focused on a single substance and its cutaneous signs and never on the entire group of substances abused with respect to their dermatological manifestations. In this one-of-a-kind study, we focused on dermatological manifestations among substance users as a comprehensive cluster and attempted to study these manifestations as a group.
In the present study, pruritus was the most common dermatological symptom among substance users, which was statistically significant among heroin users (P < 0.001). Heroin and other opiates are known to induce pruritus. Many mechanisms have been put forward to explain itching post-heroin use. Opioid-induced itch has been suggested to be mediated primarily through the m-opioid receptor (MOR), a key receptor for opiates. Xian-Yu Liu et al. demonstrated that this itch-specific receptor, known as MOR1D, appears to operate independently from receptors that relieve pain. Maurer et al. in their study found pruritus present in 55.4% of cases in a sample size of 78, all being heroin users. They also found higher levels of histamine in cases compared to controls in the study. Elevated histamine levels due to mast cell degranulation and histamine release might have been a consequence of immune activation due to regular heroin use. Our study found pruritus occurring immediately following heroin use with a duration lasting up to several days as found by Hennings et al. There was a predilection of itching towards the nasal and facial areas of the cases in our study, and such findings have not been reported so far in other studies.
Staining of the fingers and nails with resulting hyperpigmentation from pale yellow to intense brown color, most commonly of the middle finger, followed by the index finger and thumb of the dominant hand, was seen in the majority of cannabis smokers (64.4%) and heroin smokers (57.1%) in our study. The mechanism of development of such lesions is similar to the development of tobacco staining of fingers where such lesions are seen due to repeated exposure to smoke and tar in smoke as mentioned by Chauhan et al. Kalman et al. in their study found two- to four-fold increase in the consumption of tobacco and thus staining of fingers in substance users compared to the general population.
Hyperhidrosis was seen in a few cases in the present study, specifically in opioid users, whereas it was seen in 39.6% of heroin users. Opioids are recognized as potent stimulators of mast cell degranulation, and this is thought to be the main mechanism for their diaphoretic action, resulting in excessive perspiration in heroin users. Cheshire et al. found hyperhidrosis associated with opioid use in their study.
Thomson et al. in their study found periodontal disease in cannabis users where they determined three cannabis exposure groups as “No exposure” (32.3%), “Some exposure” (47.4%), and “High exposure” (20.2%) and found periodontal disease in 6.5%, 11.2%, and 23.6%, respectively, concluding cannabis smoking as a risk factor for periodontal disease that is independent of the use of tobacco. Schulz-Katterbach et al. found cannabis use associated with significantly higher dental decays values (P = 0.0001) than the control group in their study. Similarly, Al Bush et al. in their study with a sample size of 100 found cannabis and heroin use were associated with dental decay and periodontal disease. Likewise, in the present study, tooth decay and periodontal disease were seen in 21.2% of cannabis users as well as in 19% of heroin users, concluding that both cannabis and heroin use are associated with dental decay and periodontal disease and are risk factors for these oral conditions, though the difference between the two substances was not statistically significant (P = 0.427).
Some dermatological manifestations were specific to IDUs in the present study. The presence of linear post-inflammatory hyperpigmentation at intravenous injection sites (track marks) resulting from damage and consequent sclerosis of the underlying veins and sooting tattoos formed due to injection of heroin with hot needles was seen exclusively in injectable heroin users (93.1%) in our study. Coull et al. in their study with a sample size of 204 IDUs, where 60% of the cases had some skin manifestation, found a prevalence of 47% cases among them having track marks. The antecubital fossa of the non-dominant arm was the most commonly affected site in the present study similar to the description by Del Giudice. Such lesions have been described in the previous literature and are known as telltale signs or stigmata of injectable drug use.
In the present study, 30.7% of injectable heroin users ended up with the presence of skin popping scars. Once the veins become sclerotic and inaccessible, drug users often resort to intradermal, subcutaneous, and sometimes intramuscular drug administration, also known as “skin popping.” This method of drug administration usually results in deep, circular, punched-out looking atrophic scars known as skin popping scars. This can be considered as another telltale sign of injectable drug use as described by Grunebaum et al. Reports from European researchers show an apparent increase in skin popping among drug users.
Coull et al. in their study found abscesses in the past or currently present in 75% cases followed by lumps in 48%, and leg ulcers in 25% cases. Similarly, in our study, 18.8% of injectable drug users had active skin ulcerations and skin and soft tissue infections. Several independent risk factors are present among injection drug abusers for developing SSTIs, the most important being skin popping which causes tissue trauma and introduces bacteria into the skin. It may also introduce adulterant substances, which can concentrate locally and irritate the skin.
In the present study, 8.8% of injectable heroin users had the presence of puffy hands, which develops after long-term intravenous drug addiction. It was characterized by a non-pitting edema, affecting the dorsal side of fingers and hands, especially non-dominant hand with a puffy aspect similar to the description by Amode et al. Female gender, injections in the hands and in the feet, and the absence of tourniquet have been found to be significant risk factors for puffy hand syndrome in the past literature. In our study, male gender was predominant and the most common site was non-dominant hand followed by dominant hand, and in most of the cases history of tourniquet use while injecting heroin was lacking.
In our study, 13.7% of cannabis users had the presence of periorbital hyperpigmentation. Premature aging such as periorbital darkening, hair loss, and graying of hair has been associated with cannabis use in the literature. Maharaj et al. have described an increased cornification of the radial aspect of the thumb just distal to the pulp prominence on close inspection which is more easily palpated as a thickening of the corneal layer of the palmar skin of the thumb in 27 cases of heavy smoking which they have described to be due to the result of repeated friction of the thumb against the roller of cigarette lighters. Similarly, in our study, we could also find the presence of frictional callosities, especially over thumb and fingers (12.2%), developed secondary to hand rubbing of cannabis and excessive lighter use by cannabis smokers. In our study, the prevalence of acne vulgaris among substance users was 17.2%; however, the prevalence of acne vulgaris was significantly less among cannabis users (9.3%) (P < 0.001). The decreased prevalence of acne among these cases can be attributed to sebostatic effects of cannabis. Oláh et al. showed that cannabidiol (CBD) derived from Cannabis sativa might improve acne vulgaris through a sebostatic mechanism. CBD had antiproliferative effects on both keratinocytes and sebocytes, thus decreasing the formation of comedones and production of sebum as well as demonstrable antimicrobial activity.
Larkin et al. in a systemic review of hospital-based studies found thirteen studies reporting a positive association between hesitation cuts/repetition of self-harm and drug abuse/dependence. In the current study as well, 16.3% cases had the presence of hesitation cuts, most commonly over forearms.
This was a clinical study, and the sample size in our study was small to make any concrete inferences regarding the exact prevalence and pattern of these disorders.
Due to the cross-sectional design of the study, we could not infer the presence or absence of dermatological manifestations at other times.
Only patients motivated for treatment were examined because of the presence of bias of being registered in drug de-addiction centers.
The presence of psychological disorders and systemic comorbidities could also lead to a few dermatological manifestations present in the study. There was no comparative group.
Dermatological manifestations are quite prevalent among substance users in the population of Kashmir. Pruritus with temporal relation to substance use, stigmata of injectable drug use including track marks and sooting tattoos, atrophic scars at injection sites, active skin ulcers, and skin and soft tissue infections, and hyperhidrosis are among important dermatological clues for detecting substance use. Recognition of such cutaneous signs is important in these cases for more effective diagnosis and treatment. Creating awareness regarding such manifestations and their probable association with substance use is also imperative.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
1. Han B, Compton WM, Blanco C, DuPont RL National trends in substance use and use disorders among youth J Am Acad Child Adolesc Psychiatry 2017 56 747–54 e3
2. Hennings C, Miller J Illicit drugs:What dermatologists need to know J Am Acad Dermatol 2013 69 135–42
3. Coull AF, Atherton I, Taylor A, Watterson AE Prevalence of skin problems and leg ulceration in a sample of young injecting drug users Harm Reduct J 2014 11 22
4. Sharma YK, Shukla P, Nayak R, Kothari P, Gupta A Association of dermatoses with duration and quantum of alcohol intake:A comparative cross-sectional study Indian J Dermatol 2017 62 184–90
5. Kumara LS, Rangaraj M, Karthikeyan K Cutaneous manifestations of chronic alcoholism:A cross sectional study in a tertiary care centre in South India Int J Res Dermatol 2016 2 4
6. Hale T, Soheila N, Mehdi S, Soma A Observational study of dermatological manifestations in patients admitted to a tertiary poison center in Iran Turk J Med Sci 2018 48 136–41
7. Bruno MCT, Vilela MAC, Oliveira CABM Study on dermatoses and their prevalence in groups of confirmed alcoholic individuals in comparison to a non-alcoholic group of individuals An Bras Dermatol 2013 88 368–75
8. Jayaraman S, Richardson D, Conrad M, Eichler C, Schecter W Mycotic pseudoaneurysms due to injection drug use:A ten-year experience Ann Vasc Surg 2012 26 819–24
9. Inci R, Kelekci KH, Oguz N, Karaca S, Karadas B, Bayrakci A Dermatological aspects of synthetic cannabinoid addiction Cutan Ocul Toxicol 2017 36 125–31
10. Dahlman D, Håkansson A, Kral HA, Wenger L, Ball LE, Novak PS Behavioral characteristics and injection practices associated with skin and soft tissue infections among people who inject drugs:A community-based observational study Subst Abus 2017 38 105–112
11. Liu X-Y, Liu Z-C, Sun Y-G, Ross M, Kim S, Tsai F-F, et al Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids Cell 2011 147 447–58
12. Maurer U, Kager C, Fellinger C, Loader D, Pollesböck A, Spitzer B, et al Risk of anaphylaxis in opioid dependent persons:Effects of heroin versus substitution substance Subst Abuse Treat Prev 2014 9 12
13. Chauhan V, Sharma R, Thakur S Tell-tale signs of a chronic smoker Lung India 2013 30 79–81
14. Kalman D, Morissette SB, George TP Co-morbidity of smoking in patients with psychiatric and substance use disorders Am J Addict 2005 14 106–23
15. Cheshire WP, Fealey RD Drug-induced hyperhidrosis and hypohidrosis:Incidence, prevention and management Drug Saf 2008 31 109–26
16. Thomson WM, Poulton R, Broadbent JM Cannabis smoking and periodontal disease among young adults JAMA 2008 299 525–31
17. Schulz-Katterbach M, Imfeld T, Imfeld C Cannabis and caries--does regular cannabis use increase the risk of caries in cigarette smokers? Schweiz Monatsschr Zahnmed 2009 119 576–83
18. Al Bush MM An oral cavity profile in illicit Drug abusers? J Indian Soc Periodontol 2019 23 517–24
19. Del Giudice P Cutaneous complications of intravenous drug abuse Br J Dermatol 2004 150 1–10
20. Grunebaum A, Skupski D Skin popping scars - a telltale sign of past and present subcutaneous drug abuse Case Rep Perinat Med 2012 1 37–9
21. Brett MM, Hallas G, Mpamugo O Wound botulism in the UK and Ireland J Med Microbiol 2004 53 555–61
22. Galldiks N, Nolden-Hoverath S, Kosinski CM, Stegelmeyer U, Schmidt S, Dohmen C, et al Rapid geographical clustering of wound botulism in Germany after subcutaneous and intramuscular injection of heroin Neurocrit Care 2007 6 30–4
23. Gontijo B, Bittencourt FV, Lourenço LFS Skin manifestations of illicit drug use An Bras Dermatol 2006 1 307–17
24. Amode R, Bilan P, Sin C, Marchal A, Sigal MA, Mahé E Puffy hand syndrome revealed by a severe staphylococcal skin infection Case Rep Dermatol Med 2013 2013 376060
25. Andresz V, Marcantoni N, Binder F Puffy hand syndrome due to drug addiction:A case-control study of the pathogenesis Addiction 2006 101 1347–51
26. Raiker N, Aouthmany M, Ezra N Dermatologic signs and symptoms of substance abuse J Clin Exp Dermatol Res 2016 7 337
27. Maharaj D, Naraynsingh V Cigarette lighter thumb Am J Med 2001 110 506
28. Oláh A, Tóth BI, Borbíró I, Sugawara K, Szöllõsi AG Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes J Clin Invest 2014 124 3713–24
29. Appendino G, Gibbons S, Giana A, Pagani A, Grassi G Antibacterial cannabinoids from Cannabis sativa:A structure-activity study J Nat Prod 2008 71 1427–30
30. Larkin C, Di Blasi Z, Arensman E Risk factors for repetition of self-harm:A systematic review of prospective hospital-based studies PLoS One 2014 9 e84282